The Use of Bacillus Calmette-Guerin in the Therapy for Superficial Bladder Carcinoma.
- Author:
Bup Wan KIM
1
;
Sae Kook CHANG
;
Dong Taek CHO
Author Information
1. Department of Urology, School of Medicine, Kyungpook National University, Taegu, Korea.
- Publication Type:Original Article
- Keywords:
BCG;
bladder cancer
- MeSH:
Administration, Intravesical;
Bacillus*;
Biopsy;
Carcinoma, Transitional Cell;
Humans;
Immunotherapy;
Korea;
Mycobacterium bovis;
Skin Tests;
Urinary Bladder Neoplasms;
Urinary Bladder*
- From:Korean Journal of Urology
1988;29(5):706-712
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Intravesical instillation of Tice Chicago strain BCG(120mg) was given to 21 patients with biopsy proved superficial transitional cell carcinoma. A short course therapy group consisting of 6 or 8 weekly instillation was followed by monthly cystoscopic examination and cytology in 13 patients. Maintenance therapy consisting of twice dose of BCG and monthly 4 courses booster instillation were given to 15 patients considering of high risk group. We evaluated PPD skin test & Multi-test responsiveness in both cancer group and 22 control group. Of 21 cancer patients whose preinstillation PPD negativeness was 75% and convert rate from negative to positive was 75% and in control group their PPD negative ratio is also 70%(9 cases). Side effects were minor and self limiting in the majority of patients without using antituberculors regimen. Although our limited experience, BCG immunotherapy may be also the current treatment of choice for patients with superficial bladder cancer and will require further investigation especially in our Korea.
